What guidance did Neogenomics's management provide for the next earnings period?

Did Neogenomics beat or miss consensus estimates last quarter?

What is the market's earnings forecast for Neogenomics next quarter?

What is the revenue and EPS growth rate for Neogenomics year over year?

What factors drove the changes in Neogenomics's revenue and profit?

What were the key takeaways from Neogenomics's earnings call?

What were the key takeaways from Neogenomics’s earnings call?

What does Neogenomics do and what are its main business segments?

**Key Takeaways:**
- **Revenue Momentum**: 12% YoY growth driven by 24% NGS expansion and 15% clinical volume growth.
- **MRD Breakthrough**: RaDaR ST launch in Q1 2026 targets $30B MRD market, with pharma bookings starting Q4 2025.
- **Operational Efficiency**: LIMS consolidation and sales force expansion to drive 2026+ margin improvement.
- **Strategic Focus**: Community oncology consolidation (80%+ cancer care) and AI-driven MRD innovation.

**【CEO Summary Section】**
- **Revenue Growth**: Total revenue of $188 million, up 12% YoY, driven by 18% clinical revenue growth. NGS revenue grew 24% YoY, accounting for 33% of clinical revenue.
- **Strategic Initiatives**: Secured court ruling to commercialize RaDaR ST MRD assay, launching in Q1 2026. Pathline acquisition on track to accelerate Northeast growth, with integration complete.
- **Customer Experience**: Emphasized fast turnaround times (e.g., 7-day average for PanTracer LBx) and comprehensive oncology menu (over 500 tests) to consolidate community oncology send-out.
- **Guidance**: Reiterated full-year 2025 guidance: $720-726 million revenue, $41-44 million adjusted EBITDA, and $108-116 million net loss.

**【CFO Financial Commentary】**
- **Financial Highlights**: Adjusted EBITDA of $12.2 million (9th consecutive quarter of positive earnings). Operating expenses up 12% YoY due to sales team expansion and Pathline-related costs.
- **Key Metrics**: AUP increased 3% YoY (excluding Pathline), clinical test volumes up 15%. Nonclinical revenue declined 27% YoY, consistent with strategic focus on clinical growth.
- **Cash Position**: $164 million cash on hand, supporting investments in growth and operational efficiency.

**【Q&A Key Highlights】**
- **MRD Growth**: RaDaR ST expected to contribute $30 million+ in 2026, with pharma bookings starting Q4 2025. MRD market $30B+ at 30% CAGR, with Neo targeting 10%+ penetration.
- **LIMS Rollout**: LIMS consolidation to reduce costs and improve workflow efficiency, with benefits materializing in 2026-2027.
- **Sales Force Expansion**: 2025 sales team additions driving 10%+ volume growth, with further expansion planned for 2026.
- **PanTracer LBx**: Launched in Q3, early uptake strong but reimbursement-dependent, with potential 2026 revenue contribution.
- **Pharma Recovery**: Pharma business expected to remain soft in 2026, with recovery in 2027 tied to MRD adoption and new product launches.

NeoGenomics, Inc. (NEO) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

NEO

NEO fundamentals

You can ask Aime